FY2026 EPS Estimates for Prothena Increased by HC Wainwright

Prothena Corporation plc (NASDAQ:PRTA) – Equities research analysts at HC Wainwright raised their FY2026 earnings estimates for shares of Prothena in a research note issued on Friday, February 20th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings of $1.81 per share for the year, up from their previous estimate of $1.80. HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share. HC Wainwright also issued estimates for Prothena’s Q4 2026 earnings at $1.14 EPS.

Prothena (NASDAQ:PRTA) last posted its earnings results on Thursday, February 19th. The biotechnology company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.05. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.67 million. Prothena had a negative net margin of 2,520.57% and a negative return on equity of 62.53%.

Several other equities research analysts have also recently commented on the company. Royal Bank Of Canada raised their target price on Prothena from $11.00 to $12.00 and gave the stock a “sector perform” rating in a research note on Friday. Piper Sandler boosted their target price on shares of Prothena from $15.00 to $36.00 and gave the company an “overweight” rating in a research report on Tuesday, October 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Prothena in a report on Monday, December 29th. Wall Street Zen upgraded shares of Prothena from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Chardan Capital upgraded Prothena to a “strong-buy” rating in a research note on Wednesday, November 19th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $22.00.

Prothena Stock Performance

Shares of NASDAQ PRTA opened at $9.02 on Monday. The business has a fifty day moving average of $9.26 and a two-hundred day moving average of $9.42. Prothena has a 52-week low of $4.32 and a 52-week high of $16.67. The stock has a market cap of $485.55 million, a PE ratio of -1.99, a PEG ratio of 1.89 and a beta of -0.11.

Institutional Trading of Prothena

Institutional investors have recently modified their holdings of the company. Rubric Capital Management LP raised its position in Prothena by 138.7% during the fourth quarter. Rubric Capital Management LP now owns 3,677,331 shares of the biotechnology company’s stock valued at $35,119,000 after buying an additional 2,136,958 shares during the period. State Street Corp grew its stake in Prothena by 151.7% during the 4th quarter. State Street Corp now owns 2,267,802 shares of the biotechnology company’s stock valued at $21,658,000 after acquiring an additional 1,366,764 shares in the last quarter. Armistice Capital LLC increased its holdings in shares of Prothena by 1.8% in the 2nd quarter. Armistice Capital LLC now owns 2,236,000 shares of the biotechnology company’s stock valued at $13,573,000 after purchasing an additional 40,000 shares during the period. Palo Alto Investors LP lifted its position in shares of Prothena by 3.9% in the third quarter. Palo Alto Investors LP now owns 1,324,028 shares of the biotechnology company’s stock worth $12,923,000 after purchasing an additional 49,275 shares in the last quarter. Finally, Federated Hermes Inc. lifted its position in shares of Prothena by 116.2% in the second quarter. Federated Hermes Inc. now owns 1,181,087 shares of the biotechnology company’s stock worth $7,169,000 after purchasing an additional 634,832 shares in the last quarter. Institutional investors and hedge funds own 97.08% of the company’s stock.

Prothena News Summary

Here are the key news stories impacting Prothena this week:

• Positive Sentiment: Q4 EPS slightly beat consensus (GAAP loss per share modestly narrower than expected), showing improvement versus a year ago — a near‑term positive signal for financial trajectory. Prothena Press Release (Q4 & FY2025)
• Positive Sentiment: Analyst support: RBC raised its price target from $11 to $12 (sector perform), implying meaningful upside from current levels — this can provide some analyst‑driven buying interest. Benzinga
• Neutral Sentiment: Management highlighted upcoming partner milestones and program catalysts for 2026; these are potential positive binary events but timing/outcomes remain uncertain. Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus
• Neutral Sentiment: Full earnings call transcript and highlights are available for investors to parse program updates and management tone — useful for judging near‑term execution risk. Earnings Call Transcript (Seeking Alpha)
• Negative Sentiment: Revenue missed materially ($0.02M reported vs. ~$0.67M expected), underscoring current lack of commercial receipts and heightening sensitivity to financing and partnership milestones. Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: Company provided 2026 cash‑burn guidance (planned spend and runway), which may pressure shares if investors see a need for near‑term equity financing or dilution. Business Wire — Q4 & FY2025 Results and Guidance

About Prothena

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.